A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

We thank Yutaka Shimazu for his constructive comments on our HD21 trial.1 In the PET-2 positive cohort, 165 (69%) of 240 patients treated with brentuximab vedotin, etoposide, cyclophosphamide, ...

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Researchers sought to determine whether patients with T-ALL would be responsive to salvage therapy with homoharringtonine, cytarabine, and aclarubicin.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Immunoncology developer Prescient Therapeutics (ASX:PTX) has opened its first trial site for its phase 2a study into the ...

Clinical-stage oncology company Prescient Therapeutics Ltd has opened the first clinical site for its Phase 2a study of ...